Last reviewed · How we verify
Attenuated Hepatitis A Vaccine, H2 Strain
The Attenuated Hepatitis A Vaccine, H2 Strain, works by introducing a live, weakened form of the hepatitis A virus to stimulate an immune response.
The Attenuated Hepatitis A Vaccine, H2 Strain, developed by the Jiangsu Province Centers for Disease Control and Prevention, is a live attenuated vaccine designed to prevent hepatitis A infection. This vaccine is not approved by the FDA but is used in China. It is administered as a single dose and has shown high efficacy in clinical trials. The vaccine's mechanism involves the introduction of a weakened form of the virus to stimulate an immune response without causing disease. Common side effects include injection site reactions, fever, and headache. The vaccine is generally well-tolerated, but it is contraindicated in individuals with a history of severe allergic reaction to any component of the vaccine.
At a glance
| Generic name | Attenuated Hepatitis A Vaccine, H2 Strain |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | Live attenuated vaccine |
| Target | Hepatitis A virus |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains a live, attenuated strain of the hepatitis A virus (H2 strain) that is capable of replicating in the host but does not cause disease. This replication triggers an immune response, leading to the production of antibodies against the virus.
Approved indications
Common side effects
- Injection site pain
- Fever
- Headache
Key clinical trials
- The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines (PHASE4)
- Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
| CN1012345678 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: